联系客服

300294 深市 博雅生物


首页 公告 博雅生物:2023年度财务决算报告

博雅生物:2023年度财务决算报告

公告日期:2024-03-23

博雅生物:2023年度财务决算报告 PDF查看PDF原文

            华润博雅生物制药集团股份有限公司

                  2023年度财务决算报告

    华润博雅生物制药集团股份有限公司(以下简称公司)2023年12月31日合并及母公司资产负债表,2023年度合并及母公司利润表、合并及母公司现金流量表、合并及母公司所有者权益变动表,以及财务报表附注业经安永华明会计师事务所(特殊普通合伙)审计,并且被出具标准无保留意见的审计报告。

    现将公司(合并)2023年度财务决算的相关情况汇报如下:

    一、主要会计数据和财务指标

                                                                    单位:元

      项目            2023 年            2022 年        本年比上年增减        2021 年

营业收入(元)        2,651,979,506.66      2,758,701,315.10            -3.87%  2,650,528,421.87

归属于上市公司股东    237,465,593.87        432,197,553.97            -45.06%    344,528,999.52
的净利润(元)
归属于上市公司股东

的扣除非经常性损益    143,075,746.77        392,124,538.69            -63.51%    293,492,852.21
的净利润(元)

经营活动产生的现金    641,727,504.66        596,437,198.85              7.59%  1,345,377,085.21
流量净额(元)

基本每股收益(元/股)            0.47                0.86            -45.35%            0.79

稀释每股收益(元/股)            0.47                0.86            -45.35%            0.79

加权平均净资产收益            3.28%              6.18%  减少 2.90 个百分点            7.83%


      项目            2023 年末          2022 年末      本年末比上年末增      2021 年末

                                                                减

资产总额(元)        7,828,900,301.89      8,033,175,408.45            -2.54%  7,621,775,902.48

归属于上市公司股东    7,319,750,577.78      7,185,634,486.84              1.87%  6,829,074,243.57
的净资产(元)

    二、财务状况、经营成果、现金流量分析

    (一)财务状况分析

    资产、负债项目重大变动情况

                                                                    单位:元

                  2023 年末                2023 年初        比重增

  项目        金额      占总资      金额      占总资    减          重大变动说明

                          产比例                  产比例

应收票据            0.00    0.00%      91,904.40    0.00%  0.00%  主要系商业承兑汇票到期

                                                                    所致

                                                                    主要系转让复大医药、天
应收账款  209,836,815.66    2.68%  461,706,430.03    5.75%  -3.07%  安药业的股权及回款提升
                                                                    所致

应收款项                                                            主要系转让复大医药、天
融资        66,078,942.62    0.84%  105,223,341.33    1.31%  -0.47%  安药业的股权及票据到期
                                                                    所致

                                                                    主要系转让复大医药、天
预付款项    4,667,704.75    0.06%    9,658,778.52    0.12%  -0.06%  安药业的股权及收货到票
                                                                    核销预付款所致

其他应收                                                            主要系转让复大医药、天
款        264,403,475.84    3.38%  100,619,970.80    1.25%  2.13%  安药业股权的剩余应收股
                                                                    权转让款所致

其他流动                                                            主要系预缴税费下降所致
资产        1,766,406.94    0.02%    3,591,801.00    0.04%  -0.02%

在建工程                                                            主要系浆站建设及 PCC 技
            39,936,463.03    0.51%    69,342,603.44    0.86%  -0.35%  改项目转固所致

使用权资                                                            主要系转让复大医药股权
产          2,448,954.70    0.03%    13,586,783.54    0.17%  -0.14%  所致

开发支出    53,220,110.15    0.68%    37,882,112.89    0.47%  0.21%  主要系研发投入增加所致

                                                                    主要系转让复大医药、天
商誉        72,612,799.46    0.93%  663,841,978.78    8.26%  -7.33%  安药业的股权及新百药业
                                                                    商誉减值所致

其他非流                                                            主要系购买大额可转让存
动资产    146,181,971.81    1.87%    15,541,619.29    0.19%  1.68%  单及转让复大医药尾款所
                                                                    致

应付票据                                                            主要系浆站建设、研发投
            49,744,528.62    0.64%    33,081,497.01    0.41%  0.23%  入等票据支付增加所致

                                                                    主要系转让复大医药、天
应付账款    76,605,435.31    0.98%  270,376,884.55    3.37%  -2.39%  安药业的股权及新百药业
                                                                    货款结算所致

                                                                    主要系转让复大医药、天
合同负债    12,205,635.32    0.16%    20,576,036.12    0.26%  -0.10%  安药业的股权及发货核销
                                                                    预收款所致

                                                                    主要系转让复大医药、天
应交税费    24,469,312.28    0.31%    51,504,607.76    0.64%  -0.33%  安药业的股权且处置天安
                                                                    药业亏损所致

一年内到                                                            主要系偿还到期的长期借
期的非流      907,054.30    0.01%    24,987,985.07    0.31%  -0.30%  款所致

动负债

其他流动                                                            主要系合同负债减少影响
负债        1,083,642.25    0.01%    2,350,484.00    0.03%  -0.02%  待转销项税减少所致

租赁负债                                                            主要系转让复大医药股权
            1,402,741.71    0
[点击查看PDF原文]